Related references
Note: Only part of the references are listed.miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer
Brian D. Adams et al.
CANCER RESEARCH (2016)
New Strategies in Breast Cancer: Immunotherapy
Lajos Pusztai et al.
CLINICAL CANCER RESEARCH (2016)
Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports
Kyung-Do Byun et al.
JOURNAL OF BREAST CANCER (2016)
Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases
Rachel A. Freedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial
Nadia Harbeck et al.
LANCET ONCOLOGY (2016)
Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial
Sarah B. Goldberg et al.
LANCET ONCOLOGY (2016)
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
Won-Young Park et al.
CANCER RESEARCH AND TREATMENT (2016)
Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
Leisha A. Emens et al.
CANCER RESEARCH (2015)
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases
Ishwaria M. Subbiah et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial
Javier Cortes et al.
LANCET ONCOLOGY (2015)
Therapeutic strategies to improve drug delivery across the blood-brain barrier
Tej D. Azad et al.
NEUROSURGICAL FOCUS (2015)
Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
Nu T. Lu et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
A. M. Di Giacomo et al.
ANNALS OF ONCOLOGY (2015)
The combination of weekly trastuzumab plus vinorelbine may be preferable regimen in HER-2 positive breast cancer patients with brain metastasis
Hasan Mutlu et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients
E. A. Mittendorf et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Metastatic breast cancer subtypes and central nervous system metastases
C. Aversa et al.
BREAST (2014)
Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Cristina Saura et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
Sylvia Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology
Muhammet Ali Kaplan et al.
BREAST CANCER (2014)
A phase I study of lapatinib with whole brain radiotherapy in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancer brain metastases
Nancy U. Lin et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis
Flora Zagouri et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+advanced breast cancer
Miguel Martin et al.
EUROPEAN JOURNAL OF CANCER (2013)
Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases
Priya Kumthekar et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer
Paul W. Sperduto et al.
JOURNAL OF NEURO-ONCOLOGY (2013)
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Thomas Bachelot et al.
LANCET ONCOLOGY (2013)
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
R. Bartsch et al.
BRITISH JOURNAL OF CANCER (2012)
Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival Clinical article
Jonathan P. S. Knisely et al.
JOURNAL OF NEUROSURGERY (2012)
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial
Anna Maria Di Giacomo et al.
LANCET ONCOLOGY (2012)
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Kim Margolin et al.
LANCET ONCOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases
Nancy U. Lin et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Meningeal carcinomatosis in breast cancer: prognostic factors and outcome
Carla Rameri Alexandre Silva de Azevedo et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
Javier Cortes et al.
LANCET (2011)
An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer
G. Capri et al.
ANNALS OF ONCOLOGY (2010)
Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Robert H. Vonderheide et al.
CLINICAL CANCER RESEARCH (2010)
Systemic treatment in breast-cancer patients with brain metastasis
Cagatay Arslan et al.
EXPERT OPINION ON PHARMACOTHERAPY (2010)
Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients
Y. H. Park et al.
BRITISH JOURNAL OF CANCER (2009)
Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer
Nancy U. Lin et al.
CLINICAL CANCER RESEARCH (2009)
Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
Luis H. Camacho et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Concurrent capecitabine and whole-brain radiotherapy for treatment of brain metastases in breast cancer patients
Cyrus Chargari et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Phase 2 Trial of Temozolomide Using Protracted Low-dose and Whole-brain Radiotherapy for Nonsmall Cell Lung Cancer and Breast Cancer Patients With Brain Metastases
Raffaele Addeo et al.
CANCER (2008)
Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers
Ahmad A. Tarhini et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2008)
A new prognostic index and comparison to three other indices for patients with brain metastases: An analysis of 1,960 patients in the RTOG database
Paul W. Sperduto et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer
Nancy U. Lin et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)
Antoni Ribas
ONCOLOGIST (2008)
A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases
Fabio M. Iwamoto et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Breast cancer subtypes and survival in patients with brain metastases
Byung-Ho Nam et al.
BREAST CANCER RESEARCH (2008)
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer
Rupert Bartsch et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Breast cancer brain metastases
Xiaoyun Cheng et al.
CANCER AND METASTASIS REVIEWS (2007)
Capecitabine therapy of central nervous system metastases from breast cancer
Meltem Ekenel et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mark Barok et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Multidisciplinary management of brain Metastases
April F. Eichler et al.
ONCOLOGIST (2007)
Targeted therapy for brain metastases: Improving the therapeutic ratio
Rakesh R. Patel et al.
CLINICAL CANCER RESEARCH (2007)
Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
Hans-Joachim Stemmler et al.
ANTI-CANCER DRUGS (2007)
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma
Edgardo Rivera et al.
CANCER (2006)
Systemic high-dose intravenous methotrexate for central nervous system metastases
AB Lassman et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG)
BC Pestalozzi et al.
ANNALS OF ONCOLOGY (2006)
Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab
T Yau et al.
ACTA ONCOLOGICA (2006)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206
A Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with brain metastases from solid tumors: a Hellenic Cooperative Oncology Group (HeCOG) Phase II study
C Christodoulou et al.
JOURNAL OF NEURO-ONCOLOGY (2005)
Phase I/II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases
M Kocher et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2005)
Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system
JS Barnholtz-Sloan et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma
JC Bendell et al.
CANCER (2003)
Phase I/II clinical trial of concurrent radiochemotherapy in combination with topotecan for the treatment of brain metastases
K Grüschow et al.
EUROPEAN JOURNAL OF CANCER (2002)
Topotecan chemotherapy in patients with breast cancer and brain metastases:: Results of a pilot study
C Oberhoff et al.
ONKOLOGIE (2001)
Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases
C Christodoulou et al.
ANNALS OF ONCOLOGY (2001)
Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine
KA Jaeckle et al.
BRITISH JOURNAL OF CANCER (2001)
A phase II trial of temozolomide for patients with recurrent or progressive brain metastases
LE Abrey et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Share Paper
